Fulcrum Therapeutics, Slate Medicines to merge in all-stock deal (FULC:NASDAQ)
· seekingalpha.com
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to advance next-gen migraine therapies, backed by $245M financing.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...